BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ONC BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

Market Closed 02-20 16:00:00 EST

362.14

+7.66

+2.16%

盘后362.14

+0.000.00%

18:44 EST

High363.68	Low354.36	Vol195.59K
Open355.95	D1 Closing354.48	Amplitude2.63%
Mkt Cap43.09B	Tradable Cap27.39B	Total Shares119.00M
T/O70.50M	T/O Rate0.26%	Tradable Shares75.64M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","latestPrice":362.14,"timestamp":1771621200000,"preClose":354.48,"halted":0,"volume":195593,"hourTrading":{"tag":"盘后","latestPrice":362.14,"preClose":362.14,"latestTime":"18:44 EST","volume":1011,"amount":366158.85,"timestamp":1771631067898,"change":0,"changeRate":0,"amplitude":0.001579},"delay":0,"changeRate":0.021609117580681472,"floatShares":75641900,"shares":119000000,"eps":0.5204,"marketStatus":"Market Closed","change":7.66,"latestTime":"02-20 16:00:00 EST","open":355.95,"high":363.675,"low":354.36,"amount":70501189.76899,"amplitude":0.026278,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.5204,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":354.48,"preHourTrading":{"tag":"盘前","latestPrice":357,"preClose":354.48,"latestTime":"09:16 EST","volume":63,"amount":22390.6914,"timestamp":1771597011419,"change":2.52,"changeRate":0.007109,"amplitude":0.008463},"postHourTrading":{"tag":"盘后","latestPrice":362.14,"preClose":362.14,"latestTime":"18:44 EST","volume":1011,"amount":366158.85,"timestamp":1771631067898,"change":0,"changeRate":0,"amplitude":0.001579},"volumeRatio":1.3700289146243931,"impliedVol":0.4493,"impliedVolPercentile":0.502},"requestUrl":"/m/hq/s/ONC/tweets","defaultTab":"tweets","newsList":[{"id":"1151673050","title":"Earning Preview: BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS this quarter’s revenue is expected to increase by 39.70%, and institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1151673050","media":"Earnings Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1151673050?lang=en_us&edition=fundamental","pubTime":"2026-02-19 15:46","pubTimestamp":1771487207,"startTime":"0","endTime":"0","summary":"AbstractBEIGENE LTD SPON ADS EACH REPR 13 ORD SHS will release its quarterly results on February 26, 2026, Post Market; this preview compiles consensus expectations, last quarter’s performance,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS this quarter’s revenue is expected to increase by 39.70%, and institutional views are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC"],"gpt_icon":0},{"id":"2610193696","title":"Press Release: BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26","url":"https://stock-news.laohu8.com/highlight/detail?id=2610193696","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610193696?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:01","pubTimestamp":1770807660,"startTime":"0","endTime":"0","summary":"BeOne Medicines Ltd. , a global oncology company, will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET.This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne's plans, commitments, aspirations and goals related to BeOne's medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled \"Risk Factors\" in BeOne's most recent periodic report filed with the U.S. Securities and Exchange Commission  as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","BK4588","BK4139","BK4585","MDCO","BK4526"],"gpt_icon":0},{"id":"2610653720","title":"Is BeOne Medicines (ONC) Using InSysBio Partnership to Quietly Redefine Its R&D Risk Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2610653720","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610653720?lang=en_us&edition=fundamental","pubTime":"2026-02-09 19:22","pubTimestamp":1770636159,"startTime":"0","endTime":"0","summary":"InSysBio recently announced it has extended its collaboration with BeOne Medicines to apply mechanistic translational modeling to support selection of minimal recommended starting doses, step-up dosing regimens, and dose-escalation clinical study design for cytokine release syndrome risk management.\nThis expanded partnership highlights how advanced modeling can shape early clinical decisions, potentially improving the efficiency and safety profile of BeOne Medicines’ development...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/is-beone-medicines-onc-using-insysbio-partnership-to-quietly","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/is-beone-medicines-onc-using-insysbio-partnership-to-quietly","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","MDCO","ONC","BK4526","BK4139"],"gpt_icon":0},{"id":"2608336332","title":"Beone Medicines : Barclays Raises Target Price to $394 From $385","url":"https://stock-news.laohu8.com/highlight/detail?id=2608336332","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608336332?lang=en_us&edition=fundamental","pubTime":"2026-02-04 19:25","pubTimestamp":1770204343,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nFWN3Z00TJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK0239","688235","BK4585","ONC","BK4526"],"gpt_icon":0},{"id":"2608543823","title":"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608543823","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608543823?lang=en_us&edition=fundamental","pubTime":"2026-02-04 17:20","pubTimestamp":1770196854,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen (AMGN – Research Report) and BeOne Medicines (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-and-beone-medicines-onc-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-and-beone-medicines-onc-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","LU1061106388.HKD","LU2242646821.SGD","MDCO","LU1571399168.USD","XBI","HCSG","BK4588","LU2468319806.SGD","ONC","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0058720904.USD","BK4533","LU1057294990.SGD","BK4137","BK4526","IE0009355771.USD","LU0109394709.USD","BK4581","LU0868494617.USD","LU1023059063.AUD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","AMGN","LU0029874061.USD","BK4585","LU1983299246.USD","BK4534","XLV","LABU","BK4599","BK4139","IE0002141913.USD","LU0128526141.USD","LU0289739699.SGD","LU0889565916.HKD","LU0122379950.USD","SG9999001440.SGD","LU2089984988.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","LU2112291526.USD","LU2242652126.USD"],"gpt_icon":0},{"id":"2608614330","title":"U.S. RESEARCH ROUNDUP- Ametek, Coca-Cola, Pepsico","url":"https://stock-news.laohu8.com/highlight/detail?id=2608614330","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608614330?lang=en_us&edition=fundamental","pubTime":"2026-02-04 14:59","pubTimestamp":1770188350,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Ametek, Coca-Cola, PepsicoFeb 4 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Ametek, Coca-Cola","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nL8N3Z00I2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMG","AMDY","BALL","DVA","AZO","AMUU","BHE","KO","AMAT","AMDW","AES","BRBR","BR","ATI","ADM","CRUS","DOCS","ARCB","BBNX","PEP","CSGP","ONC","AMDG","DOX","CLX","EMR","AMD","ABNB","DY","COLM","AMDU","ASH","BC","AMDD","AME","EPD","CTMX","AMDL","CCI","CHD","BKNG","NET","DVN","APPN","AMYY","AXP","AMGN","EMN","BKR","AMR"],"gpt_icon":1},{"id":"2608488416","title":"BeOne Medicines Extends InSysBio Tie Up To Refine Oncology Trial Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2608488416","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608488416?lang=en_us&edition=fundamental","pubTime":"2026-02-02 01:26","pubTimestamp":1769966782,"startTime":"0","endTime":"0","summary":"BeOne Medicines (NasdaqGS:ONC) has extended its collaboration with InSysBio to apply mechanistic translational modeling to clinical trial design.\nThe partnership targets better dose selection and escalation strategies, with a specific focus on reducing the risk of cytokine release syndrome in upcoming studies.\nThis updated agreement aims to support the company’s clinical development plans for its novel therapies.\n\nFor you as an investor watching BeOne Medicines, the key point is that this is...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-extends-insysbio-tie-up-to-refine-oncology-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-extends-insysbio-tie-up-to-refine-oncology-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","MDCO","ONC","BK4526","BK4139"],"gpt_icon":0},{"id":"2608072004","title":"Is There Now An Opportunity In BeOne Medicines (ONC) After Strong Multi‑Year Share Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2608072004","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608072004?lang=en_us&edition=fundamental","pubTime":"2026-01-31 21:25","pubTimestamp":1769865953,"startTime":"0","endTime":"0","summary":"If you are wondering whether BeOne Medicines is attractively priced right now, the key question is how its current share price stacks up against its underlying fundamentals.\nThe stock has returned 0.3% over the last 7 days, 12.0% over 30 days, 9.4% year to date, 51.3% over 1 year and 32.5% over 3 years, while the 5 year return stands at an 8.5% decline.\nThese moves sit against a backdrop of ongoing interest in the pharmaceuticals and biotech space, where investors often react quickly to...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/is-there-now-an-opportunity-in-beone-medicines-onc-after-str","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/is-there-now-an-opportunity-in-beone-medicines-onc-after-str","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK4139","BK4526","MDCO","ONC","BK4585"],"gpt_icon":0},{"id":"1111326310","title":"Valuation Ranges of Biopharma: Insights from Innovent Biologics, Hengrui Pharmaceuticals, and BeiGene","url":"https://stock-news.laohu8.com/highlight/detail?id=1111326310","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111326310?lang=en_us&edition=fundamental","pubTime":"2026-01-30 17:06","pubTimestamp":1769763994,"startTime":"0","endTime":"0","summary":"Evaluating Biopharma stocks requires looking beyond traditional metrics, focusing instead on companies that have successfully navigated the entire drug development lifecycle—from molecule discovery...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359202008.SGD","LU1255011170.USD","BK0060","01801","LU1820825898.SGD","LU2580892862.HKD","LU0455707207.USD","LU1719994722.HKD","LU2543165471.USD","LU2580892789.USD","BK1161","LU0405327148.USD","LU1655091616.SGD","LU0359201612.USD","BK0028","BK1589","LU0307460666.USD","LU1303224171.USD","LU1580142542.USD","LU2097828474.EUR","LU1997244956.HKD","LU1781817850.SGD","LU1146622755.USD","BK4139","600276","BK4526","HK0000165453.HKD","LU0359201885.HKD","LU2148510915.USD","LU1064130708.USD","LU1997245177.USD","BK0012","06160","LU2488822045.USD","BK0196","BK0239","LU0405327494.USD","688235","BK1500","BK1588","LU2289578879.USD","01276","LU1251922891.USD","BK4585","LU2328871848.SGD","LU1770034418.SGD","BK0188","LU0502904849.HKD","LU1969619763.USD","LU2097828557.USD","LU0588546209.SGD","LU2097828631.EUR","LU1023057109.AUD","BK0183","LU1328615791.USD","LU2495084118.USD","ONC","LU1997245094.SGD","LU1064131003.USD","LU2097828714.EUR","LU2097828805.USD","LU2242644610.SGD","BK1191","BK1583"],"gpt_icon":0},{"id":"1166688867","title":"BeiGene (06160) Grants Restricted Stock Units Involving 21,000 American Depositary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1166688867","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166688867?lang=en_us&edition=fundamental","pubTime":"2026-01-30 17:00","pubTimestamp":1769763627,"startTime":"0","endTime":"0","summary":"BeiGene (06160) announced that on January 23, 2026, the Board's Compensation Committee granted restricted stock units involving a total of 21,000 American Depositary Shares to 246 grantees under the terms of the 2016 Option and Incentive Plan.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU1719994722.HKD","LU1969619763.USD","BK1500","LU1251922891.USD","06160","BK4585","LU2328871848.SGD","ONC","688235","LU1303224171.USD","BK1583","LU0307460666.USD","BK0239","BK4139","BK1588","BK4526","LU0588546209.SGD","LU1770034418.SGD"],"gpt_icon":0},{"id":"2606237814","title":"Did BeOne’s New Uptrend And Upgraded Earnings Outlook Just Shift Its (ONC) Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2606237814","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606237814?lang=en_us&edition=fundamental","pubTime":"2026-01-25 02:35","pubTimestamp":1769279753,"startTime":"0","endTime":"0","summary":"Recently, BEONE MEDICINES LTD-ADR (NASDAQ: ONC) met the Minervini Trend Template criteria, signaling a confirmed technical uptrend supported by strong earnings and steady revenue growth.\nAn interesting aspect of this development is the very large increase in analysts’ earnings estimates over the past three months, suggesting growing confidence in BeOne Medicines’ business momentum.\nAgainst this backdrop of rising earnings expectations, we’ll explore how this strengthening technical and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/did-beones-new-uptrend-and-upgraded-earnings-outlook-just-sh","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/did-beones-new-uptrend-and-upgraded-earnings-outlook-just-sh","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ONC"],"gpt_icon":0},{"id":"1168374108","title":"CICC Hong Kong Stock Connect and Hang Seng Index Adjustment Preview: Zijin Gold Intl (02259) Among Potential Hang Seng Index Additions; 44 Companies Expected to Enter Stock Connect","url":"https://stock-news.laohu8.com/highlight/detail?id=1168374108","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168374108?lang=en_us&edition=fundamental","pubTime":"2026-01-19 14:24","pubTimestamp":1768803841,"startTime":"0","endTime":"0","summary":"According to a research report from CICC, Hang Seng Indexes Company will announce the official results of the Hang Seng Index Series review after the market close on Friday, February 13, 2026, with...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2213484517.USD","02259","688235","BK1198","SGXZ62798434.SGD","513600","ONC","06181","XPEV","02833","HHImain","06160","601601","YUMC","09868","HK0000252152.HKD","LU0593848301.USD","HK0000500386.USD","LU2543165471.USD","02601","SGXZ86797644.SGD","MCHmain","09987","02328","09926","HK0000252160.HKD","BK4614"],"gpt_icon":1},{"id":"2603050601","title":"Citi Sticks to Their Buy Rating for BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603050601","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603050601?lang=en_us&edition=fundamental","pubTime":"2026-01-15 19:36","pubTimestamp":1768476990,"startTime":"0","endTime":"0","summary":"In a report released on January 13, Yigal Nochomovitz from Citi maintained a Buy rating on BeOne Medicines, with a price target of $405.00. The com...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-sticks-to-their-buy-rating-for-beone-medicines-onc-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-sticks-to-their-buy-rating-for-beone-medicines-onc-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO","ONC"],"gpt_icon":0},{"id":"2603604820","title":"HERIZON-GEA-01 Phase 3 Zanidatamab Combo Data Might Change The Case For Investing In BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603604820","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603604820?lang=en_us&edition=fundamental","pubTime":"2026-01-15 16:23","pubTimestamp":1768465435,"startTime":"0","endTime":"0","summary":"BeOne Medicines recently presented full Phase 3 HERIZON-GEA-01 results for ZIIHERA (zanidatamab) plus TEVIMBRA (tislelizumab) and chemotherapy in first‑line HER2-positive gastroesophageal adenocarcinoma at the 2026 ASCO GI Cancers Symposium in San Francisco, including an interim overall survival analysis.\nThe regimen’s high overall response rate and prolonged median duration of response, combined with BeOne’s commercial rights to ZIIHERA across much of Asia Pacific, elevate the potential...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/herizon-gea-01-phase-3-zanidatamab-combo-data-might-change-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/herizon-gea-01-phase-3-zanidatamab-combo-data-might-change-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ONC","BK4139","BK4585","BK4526","MDCO"],"gpt_icon":0},{"id":"1124618498","title":"Hong Kong Stock Movement | BEIGENE (06160) Opens Over 3% Higher, Announces Commercial Launch of Baiyueda® in China, First Batch to Cover 70 Cities Nationwide","url":"https://stock-news.laohu8.com/highlight/detail?id=1124618498","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124618498?lang=en_us&edition=fundamental","pubTime":"2026-01-14 09:34","pubTimestamp":1768354465,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) opened over 3% higher, with a gain of 3.33% to HK$210.8 at the time of writing, and a turnover of HK$16.7872 million. On January 14, the company announced via its official WeChat...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4526","BK1500","06160","ONC","688235","BK4585","BK1161","BK1583","BK1588","LU0307460666.USD","LU1719994722.HKD","LU1251922891.USD","LU0588546209.SGD","LU1770034418.SGD","LU1303224171.USD","BK0239","LU2328871848.SGD","LU1969619763.USD"],"gpt_icon":0},{"id":"2602519915","title":"Beone Medicines : Bernstein Raises to Outperform From Market-Perform; Raises Target Price to $414 From $362","url":"https://stock-news.laohu8.com/highlight/detail?id=2602519915","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602519915?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:19","pubTimestamp":1768216792,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0V2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","BK4585","ONC","BK4526","688235","BK4139"],"gpt_icon":0},{"id":"2601656233","title":"Beone Medicines : RBC Raises Target Price to $417 From $408","url":"https://stock-news.laohu8.com/highlight/detail?id=2601656233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601656233?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:30","pubTimestamp":1767871812,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90PS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONC","688235","BK0239","BK4526","BK4585"],"gpt_icon":0},{"id":"2601383883","title":"Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2601383883","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601383883?lang=en_us&edition=fundamental","pubTime":"2026-01-08 02:12","pubTimestamp":1767809520,"startTime":"0","endTime":"0","summary":"Jazz Pharmaceuticals reported Phase 3 trial results showing Ziihera helped patients with advanced HER2-positive stomach cancer live longer, with some treatments pushing survival beyond two years.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/07/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/07/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/financing/26/01/49763409/jazz-pharmaceuticals-drug-extends-survival-past-two-years-in-advanced-stomach-cancer-trial","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/financing/26/01/49763409/jazz-pharmaceuticals-drug-extends-survival-past-two-years-in-advanced-stomach-cancer-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0154245756.USD","AEIS","IE00BN0W2T93.GBP","JAZZ","BK4526","BK4533","LU0154245673.USD","ZYME","BK4139","BK4585","IE00B66KJ199.SGD","IE00B19Z4B17.USD","IE00BN0W2W23.USD","LU0320765992.SGD","PFS","ONC","BK4007","OS","LU0757428866.USD","BK4532","LU0823416689.USD","LU1815336091.USD","IE00B7SZL793.SGD","IE0031619046.USD","BK4195","LU0109394709.USD","BK4211","LU0889565916.HKD","IE00BN0W2V16.EUR","BK4157","BK4097"],"gpt_icon":0},{"id":"1131095987","title":"BEIGENE (06160) Awards Total of 53,300 Restricted Stock Units in American Depositary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1131095987","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131095987?lang=en_us&edition=fundamental","pubTime":"2026-01-07 16:54","pubTimestamp":1767776058,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) announced that on December 31, 2025, the Board of Directors and/or the Board's Remuneration Committee granted a total of 53,300 restricted stock units in the form of American...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1588","BK4526","LU1303224171.USD","LU1969619763.USD","BK4139","LU1251922891.USD","LU0588546209.SGD","BK0239","LU1719994722.HKD","LU0307460666.USD","BK1500","LU2328871848.SGD","ONC","688235","06160","BK1161","BK4585","LU1770034418.SGD"],"gpt_icon":0},{"id":"1105381988","title":"BEIGENE's BCL-2 Inhibitor \"Sotokela\" Approved for Market Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=1105381988","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105381988?lang=en_us&edition=fundamental","pubTime":"2026-01-05 18:40","pubTimestamp":1767609636,"startTime":"0","endTime":"0","summary":"On January 5th, the NMPA official website indicated that BEIGENE's BCL-2 inhibitor \"Sotokela\" has received approval in China for two indications. It is indicated for the treatment of adult patients...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0307460666.USD","LU1969619763.USD","BK1588","LU1770034418.SGD","BK4526","BK1161","BK4139","BK0239","BK4585","LU0588546209.SGD","LU1719994722.HKD","ONC","LU1303224171.USD","LU2328871848.SGD","LU1251922891.USD","BK1583","BK1500","06160","688235"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":0.0464},{"period":"1month","weight":0.06},{"period":"3month","weight":0.0415},{"period":"6month","weight":0.1545},{"period":"1year","weight":0.483},{"period":"ytd","weight":0.192}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.083709},{"month":2,"riseRate":0.7,"avgChangeRate":0.040799},{"month":3,"riseRate":0.4,"avgChangeRate":-0.025903},{"month":4,"riseRate":0.4,"avgChangeRate":0.021288},{"month":5,"riseRate":0.4,"avgChangeRate":-0.019094},{"month":6,"riseRate":0.5,"avgChangeRate":0.012468},{"month":7,"riseRate":0.8,"avgChangeRate":0.147208},{"month":8,"riseRate":0.6,"avgChangeRate":0.034201},{"month":9,"riseRate":0.6,"avgChangeRate":0.069537},{"month":10,"riseRate":0.5,"avgChangeRate":-0.004517},{"month":11,"riseRate":0.6,"avgChangeRate":0.063715},{"month":12,"riseRate":0.3,"avgChangeRate":-0.043663}],"exchange":"NASDAQ","name":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","nameEN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS,ONC,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票老虎,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票老虎国际,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS行情,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票行情,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股价,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股市,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票价格,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票交易,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票购买,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction